Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient

References

• SinghJASaagKGBridgesSL2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritisArthritis Care Res (Hoboken)201668112526545825
   PubMed Web of Science ®Google Scholar
• SmolenJSLandewéRBijlsmaJEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateAnn Rheum Dis201776696097728264816
   PubMed Web of Science ®Google Scholar
• CatayEBravoMRosaJSorianoERPrevalence of biologics monotherapy in a cohort of patients with rheumatoid arthritis in daily clinical practiceBMC Musculoskelet Disord201617111026932312
   PubMedGoogle Scholar
• EmeryPSebbaAHuizingaTWBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisAnn Rheum Dis201372121897190423918035
   PubMed Web of Science ®Google Scholar
• Engel-NitzNMOgaleSKulakodluMUse of anti-tumor necrosis factor monotherapy and adherence with non-biologic disease-modifying anti-rheumatic drugs in combination with anti-tumor necrosis factor therapy among rheumatoid arthritis patients in a real-world setting [abstractArthritis Rheum201269Suppl 10378
   Google Scholar
• PappasDAReedGWSaundersKCharacteristics associated with biologic monotherapy use in biologic-naive patients with rheumatoid arthritis in a US registry populationRheumatol Ther201521859627747494
   PubMed Web of Science ®Google Scholar
• ChoquetteDThomasOArundineMLower than expected levels of DMARD acquisition immediately pre and post biologic initiation in rheumatoid arthritis patientsArthritis Rheum201264Suppl 101841
   Google Scholar
• DetertJKlausPBiologic monotherapy in the treatment of rheumatoid arthritisBiologics20159354326028960
   PubMedGoogle Scholar
• BreedveldFCWeismanMHKavanaughAFThe PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatmentArthritis Rheum2006541263716385520
   PubMed Web of Science ®Google Scholar
• CurtisJRYangSChenLPredicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trialAnn Rheum Dis201271220621221998118
   PubMed Web of Science ®Google Scholar
• CannonGWWangBCParkGSKoenigACollierDHKeystoneECRemission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experienceClin Exp Rheumatol201331691992524237999
   PubMed Web of Science ®Google Scholar
• FechtenbaumMMd YusofMYEmeryPCertolizumab pegol in rheumatoid arthritis: current updateExpert Opin Biol Ther201414684185024654999
   PubMed Web of Science ®Google Scholar
• NashPNayiagerSGenoveseMCImmunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label studyArthritis Care Res2013655718728
   PubMed Web of Science ®Google Scholar
• LeeEBFleischmannRHallSORAL Start Investigators,Tofacitinib versus methotrexate in rheumatoid arthritisN Engl J Med2014370252377238624941177
   PubMed Web of Science ®Google Scholar
• GabayCEmeryPvan VollenhovenRADACTA Study InvestigatorsTocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trialLancet201338198771541155023515142
   PubMed Web of Science ®Google Scholar
• NakashimaYKondoMMiyaharaHIwamotoYDrug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis – focus on subcutaneous tocilizumabDrug Des Devel Ther20148913919
   PubMed Web of Science ®Google Scholar
• BurmesterGRLinYPatelREfficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trialAnn Rheum Dis201776584084727856432
   PubMed Web of Science ®Google Scholar
• RashidNLinATArandaGRates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare systemJ Med Econ201619656857526766553
   PubMed Web of Science ®Google Scholar
• Abdel-NasserAMRaskerJJValkenburgHAEpidemiological and clinical aspects relating to the variability of rheumatoid arthritisSemin Arthritis Rheum19972721231409355210
   PubMed Web of Science ®Google Scholar
• GenoveseMCFleischmannRKivitzAJSarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III studyArthritis Rheu-matol201567614241437
   PubMed Web of Science ®Google Scholar
• BruceBFriesJFThe Health Assessment Questionnaire (HAQ)Clin Exp Rheumatol2005235 Suppl 39S141816273780
   PubMed Web of Science ®Google Scholar
• StevensonMArcherRToshJAdalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation [erratum]Health Technol Assess201620351610
   Web of Science ®Google Scholar
• National Institute for Health and Care ExcellenceAdalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis, NICE technology appraisal guidance [TA130];2007 Available from: https://www.nice.org.uk/guidance/ta130Accessed October 21, 2016
   Google Scholar
• ArnettFCEdworthySMBlochDAThe American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritisArthritis Rheum19883133153243358796
   PubMed Web of Science ®Google Scholar
• AletahaDNeogiTSilmanAJ2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeArthritis Rheum20106292569258120872595
   PubMed Web of Science ®Google Scholar
• BoggsRSenguptaNAshrafTUT3 estimating health utility from a physical function assessment in rheumatoid arthritis (RA) patients treated with adalimumab (D2E7)Value Health200256452453
   Google Scholar
• BansbackNJBrennanAGhatnekarOCost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in SwedenAnn Rheum Dis2005647995100215550533
   PubMedGoogle Scholar
• MichaudKvera-LlonchMOsterGMortality risk by functional status and health-related quality of life in patients with rheumatoid arthritisJ Rheumatol2012391545922089466
   PubMed Web of Science ®Google Scholar
• AriasEUnited States life tables, 2011Natl Vital Stat Rep20156411163
   PubMedGoogle Scholar
• DiamantopoulosABenucciMCapriSEconomic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in ItalyJ Med Econ201215357658522313326
   PubMedGoogle Scholar
• WailooAJBansbackNBrennanAMichaudKNixonRMWolfeFBiologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysisArthritis Rheum200858493994618383356
   PubMedGoogle Scholar
• ClaxtonLJenksMTaylorMAn economic evaluation of tofacitinib treatment in rheumatoid arthritis: modeling the cost of treatment strategies in the United StatesJ Manag Care Spec Pharm20162291088110227579831
   PubMedGoogle Scholar
• BatticciottoARavasioRRivaMSarzi-PuttiniPEfficacy and treatment costs of monotherapy with bDMARDs in the treatment of rheumatoid arthritis in patients intolerant to or inappropriate to continue treatment with methotrexateAdv Ther20163381360137327376373
   PubMed Web of Science ®Google Scholar
• MontiSMontecuccoCBugattiSCaporaliRRheumatoid arthritis treatment: the earlier the better to prevent joint damageRMD Open20151Suppl 1e00005726557378
   PubMedGoogle Scholar
• RamiroSLandewéRvan der HeijdeDHarrisonDCollierDMichaudKDiscontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?RMD Open201511e00015526629366
   PubMedGoogle Scholar
• JacksonWLSarilumab monotherapy for RA superior in MONARCH2016 Available from: http://www.rheumatologynetwork.com/rheumatoid-arthritis/sarilumab-monotherapy-ra-superior-monarchAccessed January 10, 2018
   Google Scholar